Objective-To quantify
(J7 Epidemiol Community Health 1997;51:41 We compared cancer survival in the population of Estonians who emigrated to (in fact, took refuge in) Sweden in 1944-45 with that in the total Swedish population and with that in the Estonian population in Estonia. It In addition, survival of Estonian patients living in Sweden will be similar to that of all patients in Sweden.
Methods
Data on incident cases of cancer were obtained from the Swedish Cancer Registry3 for the Swedish residents (patients diagnosed 1974-86) and from the Estonian Cancer Registry4 for the Estonian residents (patients diagnosed 1979-85). Both registries are population based and cover the entire country. The sites studied were stomach and colon, female breast and ovary, and male lung and prostate. For the Estonians in Sweden and the Estonians in Estonia, all cases for all six sites were included in the analysis. For the total Swedish population, every fifth case for each site was included, except for ovarian cancer where every second case was included.
Each cancer patient was followed up for death through death certification, obtained in Sweden from the National Bureau of Statistics (NBS) death register, and in Estonia from the State Statistical Office. The follow up ended either with the death of the patient, or on December 31, 1988 for Estonians in Sweden, on December 31, 1989 for the Estonians in Estonia, and on December 31, 1991 for the Swedish population. The numbers of patients lost to follow up during the first five years were 58 for Estonians in Sweden, nine for Estonians in Estonia, and 39 patients from the total Swedish population. For these patients, the date of the last contact was used as the end of follow up. The cancer cases based on autopsy or death certificate only were excluded from the analyses.
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In 1979-85, the proportion of female breast cancer patients treated surgically was much smaller in Estonia than in Sweden. (According to what was recorded as surgical treatment in the cancer registries.) This difference was, however, not as great for patients aged 75 and above as it was in younger patients, suggesting that the treatment modality itself cannot be regarded as a cause of lower survival among high age patients in Estonia. The treatment differences are probably reflecting the differences in the stage of the disease, which is the main indicator of diagnostic delay. One cannot exclude underdiagnosis of slowly growing localised malignancies, which have a better prognosis, in Estonia, where there is no extensive mammographic screening programme.2 However, screening based on mammography has only a limited role in the high relative survival rates of breast cancer patients in Sweden, as it was mainly introduced after 1986, the last year included in the Swedish incident data for this study. 12 For male and female stomach cancer patients, no difference in relative survival was detected between the populations studied over the follow up-neither in younger nor older patients. However, the proportion of histologically non-verified stomach cancer cases among patients aged 75 The ovarian cancer patients in Sweden showed better survival than those in Estonia. Overall, the relative survival was poorer for high age patients than low age patients, while the excess mortality in the high age group was somewhat higher in Estonia. In prostate cancer, the patients in Sweden had better survival, whereas the excess high age mortality was much higher in Estonia than in Sweden. This finding suggests, as with breast cancer, that the diagnostic delay among patients aged 75 years and over was much longer in Estonia. Latent prostate cancer, as an additional finding in elderly men, is found more often in Sweden than in Estonia, perhaps because of differences in the frequency of transurethral resection for hyperplasia between countries.'" If this is true, then the number of patients with slowly developing tumours with a better prognosis may be much larger in Sweden.
Taken with the results of the previous study,' we 
